Clinical Trials Directory

Trials / Completed

CompletedNCT06415071

Hypertension Longitudinal Data Platform in Tianjin

Hypertension Longitudinal Data Platform Linked Electronic Health Records and Public Health Follow-up Database (HYLERP) in Tianjin, China

Status
Completed
Phase
Study type
Observational
Enrollment
1,172,280 (actual)
Sponsor
West China Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypertension is one of the leading causes of death globally, and ranks among the top four risk factors for mortality and DALYs in China. However, large-scale population based longitudinal research data source for hypertension is lacking in China. Thus, we aimed to establish the first and most extensive hypertension database in China using healthcare data from the Tianjin city. This hypertension longitudinal data platformlinked electronic medical records (EMR) system 35 stores healthcare data of 1.17 million hypertension patients, from 43 tertiary hospitals and 39 secondary hospitals, along with a public health follow-up management system. Data on demographics, diagnosis, drug prescription, laboratory test, physical examination, and cost information were collected, the median follow-up time was 4.3 \[ interquartile range (IQR): 2.7-5.8\] years, and the median number of outpatient visits was 32 (IQR: 15-64) per patient. This database can address research needs including, drug utilization pattern analysis, policy implementation evaluation, digital medical device development, and other real world evidence studies. These researches would provide robust evidence to assist improving patient health outcomes and healthcare system decision-making.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionExposures of interest would be clearly defined according to a specific research question and identified from the database

Timeline

Start date
2015-01-01
Primary completion
2021-12-31
Completion
2021-12-31
First posted
2024-05-16
Last updated
2024-05-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06415071. Inclusion in this directory is not an endorsement.